While the study by researchers at George Washington University and the University of Colorado shows that a combination therapy is more effective, the inclusion of rosiglitazone raises some concerns.
New research from the University of Cincinnati (UC) points to the naturally produced protein apolipoprotein A-IV (apoA-IV) as a potential target for a new diabetes therapeutic.
Nearly one in three hospital patients with diabetes are affected by medication mistakes that can lead to dangerously high or low blood glucose levels, checks have revealed.
On April 19, the US Food and Drug Administration issued a warning to diabetes patients not to combine the blood pressure medication aliskiren (Tekturna) with ACE inhibitors or angiotensin receptor blockers.
Allison Goldfine, M.D., Section of Clinical, Behavioral & Outcomes Research at Joslin Diabetes Center, is responding to the controversy in her editorial titled “Statins: Is It Really Time to Reassess Benefits and Risks?”
Takeda Pharmaceutical received a complete response letter from the FDA regarding alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone in type 2 diabetes.
A consumer advocacy group is calling on government regulators to withdraw a diabetes drug from Novo Nordisk, saying the injectable medication raises the risk of thyroid cancer, pancreatitis and kidney failure.
It’s not clear whether patients with type 2 diabetes gain any long-term benefit from taking the blood sugar-lowering drug metformin and insulin together rather than insulin alone.
A study suggests that the long-term benefits of this drug compared with the risks are not clearly established.
Diabetes drug Victoza (liraglutide [rDNA] injection) has been shown to be superior to Januvia (sitagliptin) in achieving body weight reduction and blood sugar control, Novo Nordisk has announced.
Albiglutide, a once-weekly formulation of a glucagon-like peptide-1 agonist, appears to be effective at controlling blood sugar compared with insulin, according to a release from GlaxoSmithKline.
Sulfonylureas have been used to treat type 2 diabetes for many, many years. However, newer agents and a better understanding of type 2 diabetes have called their role into question.
GlaxoSmithKline plans to push ahead with plans to file its experimental once-weekly diabetes drug albiglutide for regulatory approval, following the read-out from a series of clinical trials.
For patients with type 2 diabetes mellitus who are treated with aspirin, isoprostanes are overproduced, which is linked with enhanced platelet recruitment, according to a study published online March 16 in Diabetes.
Common high-blood-pressure medication appears to reverse the diabetes-related death of pancreatic beta cells, according to a University of Alabama at Birmingham study published March 22 in the journal Diabetes.
Long-term treatment with metformin is safe for preventing or delaying the development of type 2 diabetes, according to an article published in the April issue of Diabetes Care.
Conducted at St. Michael Hospital in Toronto Canada, the trial explored the safety and efficacy of twice-daily oral doses of Optina(TM), to reduce macular edema as determined by OCT (optical coherence tomography).
An experimental diabetes drug, TAK-875, demonstrated its ability to improve blood-sugar control with a low risk of hypoglycemia, according to phase 2 study results published online February 27 in The Lancet.
Metformin was first formulated in 1922. But unlike many drugs of the same era which have fallen by the wayside, it has endured, or indeed, thrived. What is so great about the #1 most prescribed diabetic drug?
XOMA Corporation (Nasdaq: XOMA) announced that its study of XMetA, the company’s fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association’s journal Diabetes.